USA MedTech: Pure Global on the EU Post-Market Data Trap

This week on MedTech Global Insights, we explore the hidden challenges of using European post-market data for FDA submissions. Following the FDA's recent guidance on Real-World Evidence (RWE), many non-U.S. manufacturers assumed their path to the American market would be easier. We reveal why that is often not the case. We break down the fundamental differences between the EU's requirements for Post-Market Surveillance and the FDA's expectations for RWE. This disconnect can lead to significant delays, unexpected costs, and jeopardized market access for companies that are not prepared. A German cardiology firm learned this the hard way. They presented years of flawless EU post-market data to the FDA, only to have their 510(k) submission stalled. The reason? The data failed to adequately represent the diverse U.S. patient population, a critical flaw that sent them back to the drawing board. 本期干货: 1. Why is robust EU MDR post-market data often insufficient for the FDA? 2. What are the key differences between a PMS report and an RWE submission? 3. How does the diversity of the U.S. patient population impact data requirements? 4. What's the number one mistake companies make when repurposing EU data for a 510(k)? 5. Can a single post-market study be designed to satisfy both EU and US regulators? 6. What specific data points does the FDA look for that the EU might not prioritize? 7. How can you identify gaps in your existing clinical data before submitting to the FDA? For more information, contact us at [email protected] or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.